Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities DOI Creative Commons

Yujing Qian,

Yujia Yin,

Xiaocui Zheng

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Jan. 7, 2024

Abstract Tumor-associated macrophages (TAMs) are a heterogeneous population that play diverse functions in tumors. Their identity is determined not only by intrinsic factors, such as origins and transcription but also external signals from the tumor microenvironment (TME), inflammatory metabolic reprogramming. Metabolic reprogramming has rendered TAM to exhibit spectrum of activities ranging pro-tumorigenic anti-tumorigenic, closely associated with progression clinical prognosis. This review implicates diversity phenotypes functions, how this heterogeneity been re-evaluated advent single-cell technologies, impact TME on TAMs. We current therapies targeting metabolism offer new insights for TAM-dependent anti-tumor immunotherapy focusing critical role different programs

Language: Английский

Macrophages in health and disease DOI Creative Commons
Matthew D. Park,

Aymeric Silvin,

Florent Ginhoux

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(23), P. 4259 - 4279

Published: Nov. 1, 2022

Language: Английский

Citations

327
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances DOI Creative Commons
Karama Makni‐Maalej, Maysaloun Merhi,

Varghese Inchakalody

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Jan. 30, 2023

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This consists of genetically engineered immune cells expressing surface receptor, called CAR, that specifically targets antigens expressed on tumor cells. hematological malignancies like leukemias, myeloma, and non-Hodgkin B-cell lymphomas, adoptive CAR-T shown efficacy in treating chemotherapy refractory patients. However, value this remains inconclusive context solid tumors is restrained by several obstacles including limited trafficking infiltration, presence an immunosuppressive microenvironment, well adverse events associated with such therapy. Recently, CAR-Natural Killer (CAR-NK) CAR-macrophages (CAR-M) were introduced complement/alternative for tumors. CAR-NK could be favorable substitute since they do not require HLA compatibility have toxicity. Additionally, might generated large scale from sources which would suggest them off-the-shelf product. CAR-M immunotherapy its capabilities phagocytosis, tumor-antigen presentation, broad currently being investigated. Here, we discuss emerging role CAR-T, CAR-NK, We also highlight advantages drawbacks compared Finally, prospective solutions potential combination therapies enhance CAR-cells immunotherapy.

Language: Английский

Citations

289
A timeline of tumour-associated macrophage biology DOI
Luca Cassetta, Jeffrey W. Pollard

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(4), P. 238 - 257

Published: Feb. 15, 2023

Language: Английский

Citations

287
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy DOI
Kun Cheng, Ning Cai, Jinghan Zhu

et al.

Cancer Communications, Journal Year: 2022, Volume and Issue: 42(11), P. 1112 - 1140

Published: Sept. 7, 2022

Abstract Multidimensional analyses have demonstrated the presence of a unique tumor microenvironment (TME) in liver cancer. Tumor‐associated macrophages (TAMs) are among most abundant immune cells infiltrating TME and present at all stages cancer progression, targeting TAMs has become one favored immunotherapy strategies. In addition, distinct origins. At early stage cancer, can provide niche for maintenance stem cells. contrast, (CSCs) or poorly differentiated key factors modulating macrophage activation. review, we first propose origin connection between precursor Macrophages undergo dynamic phenotypic transition during carcinogenesis. this course such transition, it is critical to determine appropriate timing therapy block specific markers suppress pro‐tumoral TAMs. The review provides more detailed discussion trends surface than previous reviews. Complex crosstalk occurs play indispensable roles angiogenesis, autophagy due their heterogeneity robust plasticity. interact with other by directing cell‐to‐cell contact secreting various effector molecules. Similarly, combined drive recruitment polarization. Despite latest achievements advancements treatment strategies following studies, comprehensive discussions on communication currently lacking. discussed interactions (from cell maturation), therapeutic (including chimeric antigen receptor macrophages), clinical trials hepatocellular carcinoma (HCC) intrahepatic cholangiocarcinoma (iCCA) rationale further investigation as potential target treating patients

Language: Английский

Citations

215
The biology of TREM receptors DOI Open Access
Marco Colonna

Nature reviews. Immunology, Journal Year: 2023, Volume and Issue: 23(9), P. 580 - 594

Published: Feb. 7, 2023

Language: Английский

Citations

185
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers DOI Creative Commons
Hao Zhang, Lin Liu, Jinbo Liu

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: March 21, 2023

Abstract In recent years, tumor immunotherapy has made significant progress. However, immunotherapy, particularly immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), benefits only a tiny proportion of patients in solid cancers. The microenvironment (TME) acts role immunotherapy. Studies reported that tumor-associated macrophages (TAMs), as one the main components TME, seriously affected therapeutic effect inhibitors. this review, we analyzed TAMs from epigenetic and single-cell perspectives introduced mechanisms anti-programmed death protein 1(anti-PD-1) therapy. addition, summarized combination regimens enhance efficacy elaborated on different Eventually, clinical value by influencing was discussed. These above are beneficial to elucidate poor tumors point view explore strategies improve its objective remission rate

Language: Английский

Citations

170
Roles of macrophages in tumor development: a spatiotemporal perspective DOI Creative Commons

Mathilde Bied,

William W. Ho, Florent Ginhoux

et al.

Cellular and Molecular Immunology, Journal Year: 2023, Volume and Issue: 20(9), P. 983 - 992

Published: July 10, 2023

Abstract Macrophages are critical regulators of tissue homeostasis but also abundant in the tumor microenvironment (TME). In both primary tumors and metastases, such tumor-associated macrophages (TAMs) seem to support development. While we know that TAMs dominant immune cells TME, their vast heterogeneity associated functions only just being unraveled. this review, outline various known TAM populations found thus far delineate specialized roles with main stages cancer progression. We discuss how may prime premetastatic niche enable growth a metastasis then subsequent metastasis-associated can secondary growth. Finally, speculate on challenges remain be overcome research.

Language: Английский

Citations

132
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer DOI
Nicoletta Caronni, Federica La Terza,

Francesco Maria Vittoria

et al.

Nature, Journal Year: 2023, Volume and Issue: 623(7986), P. 415 - 422

Published: Nov. 1, 2023

Language: Английский

Citations

132
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes DOI Open Access
Sayali Onkar, Neil Carleton, Peter C. Lucas

et al.

Cancer Discovery, Journal Year: 2022, Volume and Issue: 13(1), P. 23 - 40

Published: Dec. 6, 2022

Breast cancer, the most common type of cancer affecting women, encompasses a collection histologic (mainly ductal and lobular) molecular subtypes exhibiting diverse clinical presentation, disease trajectories, treatment options, outcomes. Immunotherapy has revolutionized for some solid tumors but shown limited promise breast cancers. In this review, we summarize recent advances in our understanding complex interactions between tumor immune cells at cellular microenvironmental levels. We aim to provide perspective on opportunities future immunotherapy agents tailored specific features each subtype cancer. Although there are currently over 200 ongoing trials testing immunotherapeutics, such as immune-checkpoint blockade agents, these largely restricted triple-negative HER2+ primarily focus T cells. With rapid expansion new vitro, vivo, data, it is critical identify highlight challenges unique drive next generation treatments that harness system.

Language: Английский

Citations

124
High-resolution alignment of single-cell and spatial transcriptomes with CytoSPACE DOI Creative Commons
Milad R. Vahid, Erin L. Brown, Chloé B. Steen

et al.

Nature Biotechnology, Journal Year: 2023, Volume and Issue: 41(11), P. 1543 - 1548

Published: March 6, 2023

Abstract Recent studies have emphasized the importance of single-cell spatial biology, yet available assays for transcriptomics limited gene recovery or low resolution. Here we introduce CytoSPACE, an optimization method mapping individual cells from a RNA sequencing atlas to expression profiles. Across diverse platforms and tissue types, show that CytoSPACE outperforms previous methods with respect noise tolerance accuracy, enabling cartography at

Language: Английский

Citations

85